An overview of radiochemical identity and radiochemical purity of 18F-FDG and factor affecting the RCP
Loading...
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Sharma, Sandeep
Sharma, Sandeep
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2023-08-28
Supervisors
Type
Conference Contribution - Paper in Published Proceedings
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
radiochemical purity (RCP)
nuclear medicine
nuclear medicine
ANZSRC Field of Research Code (2020)
Citation
Vyas, M., & Sharma, S. (2023). An overview of radiochemical identity and radiochemical purity of 18F-FDG and factor affecting the RCP. In Journal of Nuclear Medicine (Ed.), SNMMI-2023 , Vol. 64 (pp. T37). doi:2159-662X https://jnm.snmjournals.org/content/64/supplement_1/T37
Abstract
INTRODUCTION
The radiopharmaceutical known as fluorodeoxyglucose (18F-FDG) is the one that is utilised most frequently in PET-CT imaging. In the first place, it is applied to the diagnosis and evaluation of various stages of cancer. Because it has such a wide variety of applications, the use of 18F-FDG has expanded. In order to produce 18F-FDG, a multi-step procedure must be followed. These steps include the following: production of 18F-fluoride in a cyclotron by bombarding 16O-water with a proton beam; trapping of 18F-fluoride in an ion exchange column (QMA) in the synthesis module; elution of 18F-fluoride from the QMA column by TBA or Kryprofix solution; azeotropic drying; mannose triflate Following the completion of the purification process, the final product is collected in a sterile vial after going through a sterile filter with a pore size of 0.22 microns and being further filtered. Both the radiochemical identity (RI) and the radiochemical purity (RCP) are essential quality control characteristics; hence, it is essential that they be evaluated using techniques that have been authorised and validated, and the findings of the test need to satisfy the requirements for batch release. A low RCP can result in a low target-to-non-target ratio, an increase in blood pool or background activity, poor picture quality, a compromised diagnosis, and an increased radiation dosage to the patient as a result of a change in the biological half-life or the necessity of a repeat examination.
Publisher
Society of Nuclear Medicine and Molecular Imaging
Permanent link
Link to ePress publication
DOI
Copyright holder
Society of Nuclear Medicine and Molecular Imaging
Copyright notice
Attribution-NonCommercial 4.0 International